BioSpace News Archive

JDRF, the world’s largest private funder of type 1 diabetes research, is commemorating National Diabetes Awareness Month this November by raising awareness of T1D and the urgent need to accelerate life-changing breakthroughs to cure, prevent, and treat T1D and its complications.

Pulmatrix, Inc. (NASDAQ: PULM) today reports its third quarter results.

St. Jude Children’s Research Hospital® has announced the return of its annual holiday season St. Jude Thanks and Giving® campaign, asking shoppers from all over the country to donate through their favorite in-store and online retailers and make their mark on ending childhood cancer.

The American Podiatric Medical Association announced today a new public education campaign, Don’t Lose Your Nerve to Diabetes.

SciBase announces the first multi system order from a large dermatology practice group.

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2019.

Hillrom (NYSE: HRC) today announced financial results for its fiscal fourth quarter and full year ended September 30, 2019.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that three studies on Vectra® will be featured at the 2019 American College of Rheumatology (ACR) Annual Meeting being held Nov. 8-13, 2019 in Atlanta, GA.

Bristol-Myers Squibb Company announced the extension of the expiration date of the offers to exchange notes issued by Celgene Corporation for up to $19,850,000,000 aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene Notes.

Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the third quarter ended September 30, 2019.